Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev function by Wong, Raymond W et al.
Faculty & Staff Scholarship 
2013 
Characterization of novel inhibitors of HIV-1 replication that 
function via alteration of viral RNA processing and rev function 
Raymond W. Wong 
University of Toronto 
Ahalya Balachandran 
University of Toronto 
Matthew Haaland 
University of Toronto 
Peter Stoilov 
University of Toronto 
Alan Cochrane 
West Virginia University 
Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications 
Digital Commons Citation 
Wong, Raymond W.; Balachandran, Ahalya; Haaland, Matthew; Stoilov, Peter; and Cochrane, Alan, 
"Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA 
processing and rev function" (2013). Faculty & Staff Scholarship. 2562. 
https://researchrepository.wvu.edu/faculty_publications/2562 
This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted 
for inclusion in Faculty & Staff Scholarship by an authorized administrator of The Research Repository @ WVU. For 
more information, please contact ian.harmon@mail.wvu.edu. 
Characterization of novel inhibitors of HIV-1
replication that function via alteration of viral
RNA processing and rev function
Raymond W. Wong1, Ahalya Balachandran2, Matthew Haaland2, Peter Stoilov3 and
Alan Cochrane2,*
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada,
2Department of Molecular Genetics, University of Toronto, Toronto M5S 1A8, Canada and 3Department of
Biochemistry, West Virginia University, Morgantown, WV 26506, USA
Received April 23, 2013; Revised July 23, 2013; Accepted July 25, 2013
ABSTRACT
Expression of the complete HIV-1 genome depends
on the appropriate processing of viral RNA. Altering
the balance of viral RNA processing impairs replica-
tion of the virus. In this report, we characterize two
small molecule modulators of HIV-1 RNA processing,
8-azaguanine and 2-(2-(5-nitro-2-thienyl)vinyl)quin-
oline (5350150), which function by distinct mechan-
isms to suppress viral gene expression. Although
only 8-Azaguanine dramatically decreased accumu-
lation of HIV-1 unspliced and singly spliced RNAs and
altered splice site usage, both compounds blocked
Gag and Env expression without affecting production
of Tat (p16) and Rev regulatory proteins. Subsequent
analyses suggest that these compounds affect Rev-
mediated RNA transport by different mechanisms.
Both compounds induced cytoplasmic accumulation
of Rev, suggesting that they function, in part, by im-
pairing Rev function. This conclusion is supported by
the determination that both drugs block the nuclear
export of genomic HIV-1 RNA to the cytoplasm.
Testing confirmed that these compounds suppress
HIV-1 expression in T cells at doses below those pre-
viously used in humans for tumour chemotherapy.
Together, our observations demonstrate that small
molecules can be used to inhibit HIV-1 replication
by altering another avenue of viral RNA processing,
offering the potential for the development of novel
therapeutics for controlling this disease.
INTRODUCTION
The development of highly active anti-retroviral therapies
to suppress HIV-1 replication and prevent progression to
AIDS has saved countless lives in both the developed and
the developing worlds. However, none of the drug com-
binations in use today provide a cure for this infection,
and all necessitate strict adherence to treatment schedules
if viral suppression is to be maintained (1,2). In addition,
multiple studies have documented the ability of HIV-1 to
acquire resistance to drugs in current use and the subse-
quent transmission of resistant strains of HIV-1 between
individuals (3–8). With continued use of anti-retroviral
therapies in more diverse populations, it can be
anticipated that strains of HIV-1 resistant to current
drug cocktails will evolve and become more common
(9). As a result, efforts must continue in the search for
new anti-HIV compounds that have mechanisms of
action distinct from the drugs currently in use.
Current HIV-1 therapeutics target all the enzymatic
functions encoded by the virus (reverse transcriptase,
protease, and integrase) as well as entry into the cell
(10,11). Consequently, novel strategies, to complement
the existing therapies, should target other aspects of the
virus life cycle. One such step is the processing and expres-
sion of HIV-1 RNA. Following integration, a 9-kb tran-
script is generated from the provirus that is subsequently
processed into >40 mRNAs to allow expression of all of
the viral structural, enzymatic, and regulatory proteins
(12–15). The unspliced (US) 9-kb viral RNA can be used
to express the HIV-1 Gag and Gagpol proteins, undergo a
single splicing event to produce the singly spliced (SS)
class of viral RNAs encoding Vif, Vpr, Vpu and Env, or
go through multiple splicing events to generate multiple
spliced (MS) RNAs that produce Tat, Rev and Nef.
Balancing the extent of HIV-1 RNA splicing is critical
to replication fitness because too little splicing results in
loss of Tat and Rev, which are essential for enhancing the
transcription of the provirus and inducing expression of
the viral structural proteins, respectively. In contrast,
oversplicing of the viral RNA will impair the production
of HIV-1 structural proteins (Gag, Gagpol, and Env),
which are essential to new virus assembly (16–18).
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Because of the need to balance the processing of viral RNA,
HIV-1 has evolved various strategies to regulate the extent
of splicing as well as the use of specific splice sites, i.e. the
presence of suboptimal splicing signals, exon splicing silen-
cers, and exon splicing enhancers (12,15). However, the
virus is completely reliant on host splicing factors to
carry out the processing of its RNA. Multiple studies
during the past decade have demonstrated how changes
in abundance of various hnRNP and SR proteins, known
regulators of RNA splicing, can dramatically alter the
balance between HIV-1 US, SS, and MS RNAs by
changing the frequency of specific splice site use, resulting
in significant impairment of virus replication (12,15,19–21).
The parallel determination that activity of the SR proteins
can be modulated by multiple kinases (SRPK1, SRPK2,
CLK1, CLK2, CLK3, and CLK4) (22,23) opens up the
possibility that modulation of kinase activity could
induce changes in HIV-1 RNA splicing and, subsequently,
replication. Recent experiments by our group have con-
firmed this hypothesis by demonstrating that over-
expression of specific CLKs results in suppression of viral
Gag and Env expression, a response that can be replicated
with the use of the small molecule inhibitor, chlorhexidine,
a known modulator of CLK function (24).
A recent high-throughput screen of chemical libraries for
modulators of SMN2 alternative RNA splicing identified
several active compounds (Percifield et al., submitted for
publication). To assess whether any of these compounds
also altered HIV-1 RNA processing, we tested a subset of
these active compounds. In this report, we present data that
8-azaguanine (8-Aza) and 2-[2-(5-nitro-2-thienyl)vinyl]quin-
oline (designated 5350150) induce a marked decrease in
HIV-1 Gag and Env expression, but via distinct mechan-
isms. The 8-Aza treatment altered viral RNA abundance
and use of specific splice sites. In contrast, 5350150 had a
more limited effect on HIV-1 RNA processing. Neither
compound was found to result in marked changes in the
levels of Rev, but both blocked cytoplasmic accumulation of
HIV-1 US RNA. Further analysis revealed that these com-
pounds alter Rev subcellular distribution and transport,
suggesting that they also impair Rev function. Together,
these findings highlight the potential use of small molecules
to modulate HIV-1 RNA processing to inhibit viral replica-
tion, validating the targeting of this stage of the virus life
cycle as a potential therapeutic strategy.
MATERIALS AND METHODS
For more detailed experimental procedures, see
Supplementary Materials and Methods.
Screening of splice modulator compounds/drugs for effects
on HIV-1 RNA processing
Screens were performed using the HeLa rtTA-HIV-Mls
cell line containing a doxycycline (Dox)-inducible Tet-On
HIV-1 LAI strain provirus (25,26) as described in our
previous study (24). Compounds tested were obtained
from the ChemBridge Online Chemical Store (www.
hit2lead.com). Additional tests of compounds were per-
formed using the SupT1-based cell line, 24ST1NELSG,
obtained from J. Dougherty (UMDNJ-RWJMS, NJ)
(27). With this cell line, latent provirus expression was
induced by addition of 1.8 mM phorbol 12-myristate 13-
acetate (PMA) after similar treatment procedures
described earlier in the text. After 24 h, cells were har-
vested for RNA/protein or XTT assay of cell viability
(Sigma-Aldrich, #TOX2), whereas media or cells were
lysed with 1% TX-100 for analysis of HIV-1 gene expres-
sion by p24CA ELISA described later in the text. For ex-
periments using infected patient samples, peripheral blood
mononuclear cells (PBMCs) were first depleted of CD8+T
cells using Dynabeads CD8 (Invitrogen, #111.47D) as
outlined by manufacturer. Depletion was confirmed by
flow cytometry analysis of CD8 and CD3 surface
markers. Remaining cells were then activated by treatment
with anti-CD3 and anti-CD28 antibodies (Bio Legend
#302914 and 317304, respectively; 1 mg/ml of each) as
well as 50 U/ml of IL-2 (BD Pharmingen #554603) in
the presence or absence of indicated drugs. Media
(0.5ml) were collected every 3–4 days and replaced with
fresh media (0.5ml) containing 20U/ml of IL-2 and fresh
drug. Effect of compounds on cell viability was monitored
in parallel by XTT assay and expressed relative to control
(DMSO)-treated cells. HIV-1 growth in cultures was
monitored by p24CA ELISA of cell supernatants.
Analysis of HIV-1 expression
To monitor HIV-1 gene expression, cell culture super-
natants or cell lysates were assayed for production of
Gag protein by a HIV-1 p24CA antigen capture assay kit
(AIDS & Cancer Virus Program, NCI-Frederick,
Frederick, MD, USA). For further analysis of HIV-1
protein expression, western blots were performed on cell
lysates. The antibodies and conditions used for Tat, anti-
tubulin and isotype-specific HRP-conjugated antibodies
were used as described (24). Additional antibodies used
include anti-p24 from hybridoma 183 and mouse anti-
gp120 from hybridoma 902 (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH), mouse anti-Rev (Abcam, #ab85529) and rabbit
anti-GAPDH (Sigma, #9545). Generally, Western
Lightning-ECL (Perkin-Elmer, #NEL101) or Western
Lightning Plus-ECL (#NEL105) for anti-Rev, -Tat and
-gp120 blots was used. Signals were acquired by a
ChemiDoc MP with Image Lab software (Bio-Rad) or
exposed onto autoradiography film.
Effect of compounds on RNA processing and transport
RNA was extracted from cells, reverse transcribed and
HIV-1 mRNA levels quantitated by qRT-PCR as
described (24). The effect of drugs on HIV-1 splice site
usage within the 2-kb MS RNA class was analysed by
RT-PCR of cDNA as previously described (24). For
analysis of alternative splicing of cellular RNAs, the in-
clusion levels of 157 alternatively spliced exons and splice
sites located in 96 alternatively spliced regions of 85 genes
(Supplementary Dataset S1) was assayed by medium
throughput RT-PCR. This set of events had been previ-
ously suggested to be linked to cell transformation and
was available for use in the laboratory. Labelled PCR
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products were denatured in formamide and quantified
using an ABI Prism capillary sequencer (Life
Technologies). The inclusion level of each exon was
calculated as the amount of transcripts carrying the alter-
native exon relative to the total amount of all transcripts
detected in the PCR reaction.
To assess the impact of the various compounds on HIV-
1 US RNA subcellular distribution, cells were treated with
compounds as outlined earlier, processed and probed with
StellarisTM FISH probes comprising of a mixture of 48
Quasar 570-labelled 20-mer oligonucleotides spanning
the HIV-1 Gag coding region as outlined by the manufac-
turer (Biosearch Technologies). Images were captured by a
Leica DMR epifluorescence microscope at 630
magnification.
Effect of compounds on HIV-1 Rev subcellular
distribution
HeLa Rev cells (stably expressing HIV-1 Rev) were treated
with compounds as indicated. For studies using import or
export inhibitors, leptomycin B (LB) was added at 20 ng/ml
for 2 h before fixing, whereas cells treated with 4 mg/ml
actinomycin D were incubated for 2 h before fixation.
Slides were processed as detailed in the Supplementary
Materials and Methods and probed by primary rabbit
antibody against Rev, detected by either FITC- or Cy5-
labelled donkey anti-rabbit antibody (Jackson
Laboratories), and imaged at 630 or 400 magnification
by epifluorescence microscopy. To examine the effects of
drugs on the subcellular localization of host nuclear
proteins, fixed cells were stained with mouse anti-hnRNP
A1 (from Benoit Chabot), anti-SRp20 (Invitrogen,
# 334200), or anti-SC35 (Sigma, # S4045) antibody.
Statistical analysis
Data were analysed by Microsoft Excel and expressed as
means±standard error of the mean (SEM). Differences
between two groups of data [compound/drug treatment
versus DMSO (+Dox) control or compound/drug treat-
ment versus DMSO (+HIV) control] were compared by
two-tailed Student’s t-test. Statistical significance of
results is indicated on graphs as follows: P< 0.05, *,
P< 0.01, ** and P< 0.001, ***, unless otherwise indicated.
RESULTS
8-Aza and 5350150 suppress HIV-1 structural protein
expression
To evaluate a panel of RNA splicing modulators for their
effect on HIV-1 RNA processing, we performed initial
analyses using the HeLa rtTA-HIV-Mls cell line
described previously (24). In brief, the cell line contains
an HIV-1 LAI provirus in which the RT and IN reading
frames had been deleted, the Nef region replaced with the
rtTA activator, and multiple TetO operators inserted into
the U3 region (25,26). These modifications render expres-
sion of the provirus dependent on addition of doxycycline
(Dox) to the media. Cells were treated for 4 h with each
compound (Figure 1A) at the doses indicated, and then
viral expression was induced by Dox addition for 20 h.
Media and cells were harvested at 24 h and analysed for
alterations in HIV-1 gene expression. Analysis of cell
media from various treatments for HIV-1 p24 Gag
protein (Figure 1B) revealed that addition of either 8-Aza
or 5350150 resulted in substantial reduction in Gag expres-
sion, comparable with that seen in the absence of Dox, with
maximum suppression requiring 20–45 mM 8-Aza or
1–2 mM 5350150 (Figure 1C and D). Parallel assays of
the effects of the compounds on cell viability (XTT assay,
Figure 1C and D) determined that neither 8-Aza nor
5350150 resulted in marked reductions in viability for the
time frame or drug concentrations used.
To probe the basis of the response seen, the effects of
either compound on the expression of HIV-1 Gag, Env,
Tat, or Rev were analysed by western blot. As shown in
Figure 1E, western blots of cell lysates determined that
both 8-Aza and 5350150 reduced HIV-1 Env expression
to a similar extent as Gag. However, neither compound
had much effect on the expression of other HIV-1
proteins such as Rev and p16 Tat encoded by MS RNA
(Figure 1F) in contrast to another modulator of HIV-1
RNA processing, chlorhexidine (24). These findings
support the conclusion that general protein expression is
not affected by these compounds. Treatment with 8-Aza
caused depletion of p14 Tat, a Tat isoform encoded by
SS RNA that is dependent on Rev-mediated export, sug-
gesting that at least one of these compounds may act by
impairing Rev function.
8-Aza dramatically alters HIV-1 RNA processing
Based on the effect of these compounds on HIV-1 gene
expression and recently reported modification of RNA
splicing (Percifield et al., unpublished data), we
examined whether either compound altered HIV-1 RNA
accumulation or splice site selection. As indicated in
Figure 2A and B, qRT-PCR analyses determined that 8-
Aza treatment significantly altered HIV-1 RNA accumu-
lation (similar to chlorhexidine) (24). Treatment with this
compound reduced both US and SS viral RNA abundance
to 20% of control (+Dox) levels, whereas MS RNA ac-
cumulation was increased by 1.5-fold. In contrast,
5350150 treatment led to only modest changes, US RNA
being reduced to 60% of control, no effect on SS RNA
accumulation, and a 1.5-fold increase in MS RNA abun-
dance. In addition, there were no significant effects on the
overall RNA concentration or copies of the housekeeping
gene, actin (data not shown). In light of these alterations,
we also investigated whether either compound elicited any
changes in the frequency of splice site use. To this end,
RT-PCR was performed to amplify viral MS RNAs, and
the products were analysed by separation on denaturing
gels. As seen in Figure 2C–E, treatment with 5350150 had
little effect on the frequency of splice site usage within MS
viral RNAs. In contrast, 8-Aza induced a marked alter-
ation in splice site usage, strongly promoting the gener-
ation of Nef1 product [generated by the joining of the first
50splice site of HIV (SD1) with the last 30splice site (SA7)]
with a comparable reduction in Nef2 RNA. In addition,
there was a modest reduction in the level of Rev1/2 and
increase of Tat1 and Tat2 RNAs.
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Figure 1. Identification of 8-Aza and 5350150 as potent inhibitors of HIV-1 gene expression. HeLa rtTA-HIV-Mls cells were treated with (A)
indicated compounds (80 nM digoxin, 45 mM 8-Aza, and 2 mM 5350150) or DMSO (control) for 4 h before induction of viral gene expression with (+)
and without () Dox for 20 h. Equal concentrations of DMSO solvent were present in each treatment. (B) Cell culture supernatants were harvested
after compound treatments for analysis of HIV-1 Gag protein expression by p24CA ELISA. For information on the relative efficacy of each
compound, dose–response curves of the inhibition of HIV-1 gene expression by (C) 8-Aza (0–45mM) and (D) 5350150 (0–2 mM) were generated
(black diamonds). In parallel, the effect of compounds on cell viability was measured by XTT assay (gray circles). Data were averaged from n 5
independent experiments in (B) and n 4 in (C and D), displayed as a fraction relative to DMSO (+) control, error bars are SEM, and statistical
significant changes [between compound treatments from DMSO (+) control] indicated by asterisks as detailed in ‘Materials and Methods’ section. In
addition, cells extracts were analysed by western blot with antibodies for (E) HIV-1 structural proteins, Gag and Env, and (F) viral regulatory
factors, Rev and Tat. Blots were probed with either anti-GAPDH or anti-tubulin antibody to confirm equal loading of protein samples. Data are
representative of n 3 experiments in (E) and n 6 in (F). Lanes were cropped and assembled from the same blots.
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Figure 2. Effect of 8-Aza and 5350150 on HIV-1 and host RNA processing. The effects of 8-Aza or 5350150 on HIV-1 mRNA levels were assessed
by qRT-PCR (as described in ‘Materials and Methods’ section) of HeLa rtTA-HIV-Mls cells treated with 45 mM 8-Aza, 2 mM 5350150 or DMSO
(control) for 24 h with doxycycline before harvest. (A) The position of the primers (arrow points) used in qRT-PCR. (B) Abundance of HIV-1
unspliced (US, gray), singly spliced (SS, white), and multiply spliced (MS, black) mRNAs are shown relative to DMSO (+) controls. The house-
keeping gene b-actin served as an internal loading control for the normalization of these data. Shown are data averaged from 5 experiments, error
bars are SEM, and significant changes from control indicated by asterisks as described in ‘Materials and Methods’ section. (C-E) Changes in HIV-1
splice site use were assayed by RT-PCR of the 2 kb, MS class of HIV-1 mRNA (as outlined in ‘Materials and Methods’ section). (C) The position of







/nar/article-abstract/41/20/9471/2414802 by guest on 15 June 2020
Measuring the effect of 8-Aza and 5350150 on host cell
RNA processing
The changes in HIV-1 RNA processing in response to
either 8-Aza or 5350150 raised the question as to
whether either compound had much broader effects on
RNA splicing. To address this point, we analysed for
changes in 90 known alternative splicing events on
addition of either compound (see Supplementary
Dataset S1 for the list of genes analysed and primers
used). Primer pairs spanning the alternative splicing
events were used to amplify cDNA prepared from mock
or treated cells and changes in exon inclusion assessed by
quantitation of the amplicons following separation by ca-
pillary eletrophoresis. As shown in Figure 2F (see
Supplementary Dataset S2 for values obtained for individ-
ual genes), comparison of the level of alternative spliced
products in the presence and absence of drug revealed few
significant differences from control in the case of 5350150.
In contrast, treatment with 8-Aza was observed to induce
significant alterations in a subset of alternative splicing
events (Figure 2G). The majority of the affected RNAs
showed reduced exon inclusion in response to this drug
but none to the same extent as seen for HIV-1 RNA.
Based on these findings, it can be concluded that neither
5350150 nor 8-Aza is acting through a general perturb-
ation of the splicing process but rather are having selective
effects on a subset of host RNAs.
Effects of 8-Aza and 5350150 on HIV-1 expression in
CD4+T cells
Having demonstrated the capacity of 8-Aza and 5350150 to
suppress HIV-1 gene expression in our experimental
system, we validated their anti-viral activity in a human
CD4+T cell line (24ST1NLESG) containing an inducible
HIV-1 provirus (Figure 3A) (27). As shown in Figure 3B–C,
both 8-Aza and 5350150 resulted in a marked reduction in
HIV-1 Gag expression without significant effects on cell
viability at all concentrations shown. Additional western
blots confirmed that, although these compounds reduced
Gag expression, they had little to no effect on Tat or Rev
levels in this cell line (Supplementary Figure S2).
Subsequent analysis of the effect of the compounds on
viral RNA accumulation (Figure 3D) revealed that each
had effects similar to those seen in the HeLa rtTA-HIV-
Mls cell line; 8-Aza reduced the level of both US and SS
RNAs by 80%, whereas 5350150 decreased only US RNA
levels with no or only moderate effects on SS andMSRNA
abundance. The similarity in effect of both 8-Aza and
5350150 in two cell lines examined suggests that the
targets of these two compounds are conserved.
To validate our findings in a more relevant setting, the
ability of 8-Aza or 5350150 to suppress HIV-1 replication
was examined in the context of CD8-depleted PBMCs
obtained from treatment-naı¨ve HIV-infected patients.
Cells were incubated in the presence of lamivudine
(3-TC) (a reverse transcriptase inhibitor), 8-Aza or
5350150 and media harvested at various days after cell
activation. As shown in Figure 4A–C, both 8-Aza and
5350150 displayed significant suppression of viral growth
at a dose of 1 mM. Subsequent dose response analysis
(Figure 4D and E) determined that optimal suppression
of HIV-1 growth was obtained at 10 mM of 8-Aza or
0.5 mM of 5350150.
Both 8-Aza and 5350150 alter Rev localization
Although the alteration in HIV-1 US, SS, and MS RNAs
induced by 8-Aza could account for the reduced expres-
sion of the corresponding proteins (Gag and Env), a
similar case cannot be made for 5350150. The loss of
both Gag and Env expression on addition of 5350150 sug-
gested that it might impair Rev function. The ability of
Rev to shuttle between the nucleus and cytoplasm is
critical for its ability to export US and SS viral RNAs
to the cytoplasm and their subsequent translation
(28,29). Consequently, alterations in either Rev nuclear
import or export could reduce its function and be reflected
in changes in its subcellular distribution or localization of
Rev-dependent viral RNAs. As a test of this hypothesis,
the effect of 8-Aza or 5350150 on Rev subcellular distri-
bution was examined by immunofluorescence microscopy.
To monitor changes in Rev localization in response to
drugs, we used a HeLa Rev cell line that constitutively
expresses Rev alone at higher levels than the HeLa
rtTA-HIV-Mls cell line to better assess changes in Rev
activity. As previously reported and shown in Figure 5A,
Rev is predominately localized to the nucleus and, in par-
ticular, the nucleolus in the absence of any treatment
(DMSO) (30). However, on addition of actinomycin D
(Act. D), Rev accumulates in the cytoplasm (31). This
response can be reversed by leptomycin B (LB, an inhibi-
tor of the Rev export mediator, Crm1) (32). Act. D acts to
invert the relative rates of Rev import into and export out
of the nucleus, resulting in export being the dominant
pathway. LB, which inhibits Rev export by inactivating
Crm1, induces nuclear accumulation of Rev by allowing
only import to occur. To assess whether either 8-Aza or
Figure 2. Continued
the primers (arrow points) used to amplify MS mRNA species. (D) Representative RT-PCR gel of the levels of each MS mRNA species (arrows)
from HeLa rtTA-HIV-Mls cells treated with doxycycline and 45 mM 8-Aza, 2mM 5350150 or DMSO as performed in Figure 1. See Supplementary
Figure S1 for a description of the PCR products generated. (E) Graph summarizing the effects of 8-Aza (white), 5350150 (black), and control
treatments (gray) on the level of each MS mRNA species (x-axis) relative to the total HIV-1 MS mRNA (y-axis), displayed as percentage (%) of the
total HIV-1 MS RNA. Data were averaged from 6 experiments, error bars are SEM, and significant differences from control indicated by asterisks
as described in ‘Materials and Methods’ section. (F and G) RNAs from treatments outlined earlier in the text were subsequently used to analyse for
changes in host RNA splicing. Primer pairs spanning host RNA alternative splicing event were used to amplify from cDNA and amplicons
quantitated following resolution by capillary electrophoresis. Shown is a comparison of the level of alternative exon inclusion following treatment
with (F) 5350150 or (G) 8-Aza relative to DMSO-treated cells. Values are the average of three independent trials, and events significantly different
from control (DMSO) at P< 0.05 are indicated by open diamonds. The dotted line (grey) reflects the anticipated results if the drugs had no effect on
host RNA splicing. The solid line (black) is linear regression of the data with strength of the correlation indicated.
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5350150 also affects Rev transport, cells were treated with
either compound overnight. As shown in Figure 5B,
addition of either 8-Aza or 5350150 induced Rev accumu-
lation in the cytoplasm (similar to the effect on Act. D
treatment). Subsequent time course experiments
determined that 8-Aza induced a shift in Rev subcellular
distribution within 4 h, whereas the same effect required
16 h of treatment with 5350150 (Supplementary Figure
S3). To determine whether the effects of 8-Aza or 5350150
on Rev subcellular distribution reflected a general perturb-
ation in nuclear protein distribution, we also examined for
changes in SC35 as well as known shuttling factors,
hnRNP A1 and SRp20 (33,34). As shown in Figure 5C
and D and Supplementary Figure S4, neither 8-Aza nor
5350150 induced any detectable alteration in distribution
of other nuclear or nuclear shuttling proteins examined,
suggesting that the responses seen for Rev are selective.
Changes in Rev localization could reflect changes in one
or both of the rates of Rev nuclear export or import. To
gain insight into which process is affected, we assessed the
ability of LB to induce nuclear accumulation of Rev in the
presence of compound (as described in Figure 5A, where
LB reversed the effects of Act. D-treated cells). Cells were
treated with either 8-Aza or 5350150 overnight to induce
Rev relocalization, and then treated with LB for several
hours before fixation and analysis. As shown in Figure 5E
and Supplementary Figure S3C, LB treatment was suc-
cessful in reversing the effect of 8-Aza and Act. D on
Rev subcellular distribution, inducing complete nuclear
accumulation of Rev. Thus, 8-Aza is not solely impeding
Rev nuclear import. In contrast, LB treatment only par-
tially induced nuclear accumulation of Rev in the presence
of 5350150, indicative of reduced rate of Rev nuclear
import. The differences in response of 8-Aza and
5350150 to LB add further evidence that these compounds
function via distinct mechanisms.
To assess whether alterations in Rev localization
induced by either compound affected HIV-1 RNA trans-
port, in situ hybridization for HIV-1 US RNA was per-
formed. As shown in Figure 6, HIV-1 US RNA
(DMSO+Dox) is normally distributed throughout both
the nucleus and cytoplasm; the discrete spots in the
nucleus reflecting accumulation at the sites of provirus
transcription. However, treatment with either 5350150 or
8-Aza resulted in the detection of HIV-1 US RNA only in
discrete foci in the nucleus with little signal in the cyto-
plasm, consistent with a block in the nuclear export of
this RNA.
Figure 3. Both 8-Aza and 5350150 inhibit HIV-1 expression in a CD4+
T cell line. Using a CD4+T cell line (SupT1) stably transduced with an
HIV-1 provirus [(A) 24ST1NLESG], cells were treated with (B) 8-Aza
or (C) 5350150 at concentrations indicated, and HIV-1 provirus expres-
sion induced by addition of PMA after 4 h as detailed in ‘Materials and
Methods’ section. Equal concentrations of DMSO solvent were present
at each concentration tested. After 24 h, media were collected and the
Figure 3. Continued
levels of HIV-1 gene expression assessed by p24CA ELISA. Cell viabil-
ity was also assessed in parallel by XTT assays. (D) Effect of 8-Aza and
5350150 on HIV-1 mRNA accumulation. Following treatment of cells
with DMSO, 10 mM 8-Aza or 7 mM 5350150, virus gene expression was
induced by addition of PMA. After 24 h, total RNA was extracted and
viral RNA abundance analysed by qRT-PCR as outlined in ‘Materials
and Methods’ section. Shown are data averaged from 3 independent
experiments, error bars are SEM and significant changes from control
indicated by asterisks as described in ‘Materials and Methods’ section.
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DISCUSSION
The development of highly active anti-retroviral therapies
has saved countless lives because of its ability to suppress
virus replication, offering the prospect of a normal
lifespan for those infected with HIV-1. However, it is
not a cure (2). Further complicating treatment is the
capacity of HIV-1 to rapidly adapt to both immune and
drug pressure. Such evolution is evident in the transmis-
sion of HIV-1 strains resistant to one or more drugs
(1,4,5,7). To ensure that patients continue to have a
range of treatment options, efforts should be directed
towards the development of novel therapeutics that com-
plement the action of existing drugs. To this end, we have
been exploring the use of small molecular modulators of
alternative RNA splicing to suppress HIV-1 replication.
In support of the viability of this approach, recent work
by another group has used indole derivatives to success-
fully inhibit HIV-1 RNA processing (21,35). In this report,
we demonstrate that both 8-Aza and 5350150 are potent
suppressors of HIV-1 gene expression, each operating by
Figure 4. Suppression of HIV-1 replication in chronically infected PBMCs by 8-Aza and 5350150. CD8-depleted PBMCs from chronically HIV-1-
infected patients were activated by treatment with anti-CD3 and anti-CD28 antibodies to induce HIV-1 growth in the culture. Cells were treated with
3-TC, 8-Aza, or 5350150 (triangles), or control (DMSO, diamonds). Equal concentrations of DMSO solvent were present at each concentration of
compound/drug tested. Media were harvested at multiple times points (0-21 days) to assess virus replication by p24CA ELISA of Gag. Shown (A, B,
C) are the viral growth curves using 5 nM 3-TC, 1 mM 8-Aza or 1 mM 5350150, and (D, E) the dose response effects of the indicated drugs after 14
days in culture. Results shown are derived from assays performed on four different patient samples. Effect of drugs on cell viability (Cell Viab.) was
also tested by XTT assay and results expressed relative to DMSO-treated cells (grey circles). All error bars are SEM and statistical significance
indicated by asterisks as detailed in ‘Materials and Methods’ section.
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Figure 5. Both 8-Aza and 5350150 alter the subcellular distribution of HIV-1 Rev but not nuclear proteins of the host cell. HeLa Rev cells stably
expressing HIV-1 Rev were (A) control treated (DMSO) or incubated with 4 mg/ml of Act. D with (+) or without LB for 2 h or (B) treated with
compounds overnight with 45 mM 8-Aza or 2 mM 5350150 as described in Figure 1. After fixation and permeabilization, localization of Rev was
detected by immunofluorescence using a rabbit anti-Rev antibody followed by either a FITC- or Cy5-conjugated anti-rabbit IgG antibody. In
parallel, cells were stained with antibodies for (C) hnRNP A1 or (D) SRp20 as detailed in ‘Materials and Methods’ section. Shown are representative
images (gray scale) from three independent trials. Cells were stained with DAPI to allow imaging of the nuclei. Magnification 400. (E) To determine
whether 8-Aza or 5350150 were altering Rev localization by affecting Rev import, HeLa Rev cells were treated with DMSO, 2 h with Act. D (as a
control that induces Rev cytoplasmic accumulation) or overnight with either 45 mM 8-Aza or 2 mM 5350150, and then left untreated or treated with
LB (+LB) for 2 h before fixation. Rev distribution was assessed in individual cells by immunofluorescent staining using a rabbit anti-Rev antibody as
detailed in ‘Materials and Methods’ section. Individual cells were scored as having predominately nuclear (N>C, white), whole cell (N=C, grey) or
predominately cytoplasmic (N<C, black) patterns of Rev distribution. Shown are data averaged from three independent experiments, error bars are
SEM and significant changes from control indicated by asterisks as described in ‘Materials and Methods’ section. Representative images of the
distribution patterns observed are provided in Supplementary Figure S3C.
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different mechanisms and distinct from that previously
documented for chlorhexidine (24).
In the 1950s, 8-Aza was tested in humans as a
chemotherapeutic agent for the treatment of leukaemia
at doses between 200 and 1000mg (0.25–1.3mM).
Although some anti-tumour responses were observed, un-
desirable reactions at these doses limited its therapeutic
use (36,37). Early studies in HeLa cells indicated only
minimal reduction in cell growth rates at doses of
<40 mM 8-Aza (38). At doses of 300 mM, there was not
only a small (10%) reduction in RNA synthesis but also
a 50% decrease in total protein production in these cells
(38). These observations were consistent with 8-Aza pre-
dominately affecting translation (39), in particular initi-
ation of translation, as confirmed in subsequent studies
(40). On the other hand, parallel analysis of 8-Aza in
two in vitro translation systems (where protein production
was not dependent on RNA synthesis) failed to show any
change in protein synthesis, supporting the conclusion
that 8-Aza does not act directly on protein synthesis but
rather acts by altering the mRNA template (41,42). In
addition, other studies of this anti-metabolite confirmed
that it was incorporated in RNA but had little to no effect
on ribosomal RNA processing (43), suggesting that it was
acting at the level of mRNA. More recent studies have
identified additional effects of 8-Aza, including selective
changes in CD26 expression (44) and Von Hippel–
Lindau protein stability (45). Our study of this
compound expands its range of effects. The lack of any
alteration in Rev or p16 Tat levels in the presence of 8-Aza
indicates that the concentration required to suppress
HIV-1 structural protein expression has limited effect on
Figure 6. 8-Aza and 5350150 inhibit the transport of HIV-1 US RNA to the cytoplasm. To assess the effect of compound treatments on the
subcellular distribution of HIV-1 genomic US RNA, HeLa rtTA-HIV-Mls cells were treated overnight with DMSO (DMSO+Dox), 40 mM 8-
Aza+Dox or 2 mM 5350150 (150+Dox) for 4 h before induction of viral gene expression with Dox for 20 h as described in Figure 1. Cells were
subsequently fixed and processed for in situ hybridization of HIV-1 US RNA as detailed in ‘Materials and Methods’ section. Shown are represen-
tative distribution patterns observed from each treatment. Cells were stained with DAPI to detect nuclei (left), HIV-1 US RNA was detected in the
Cy3 channel (middle) and images were merged in colour (right). Patterns shown for each treatment are representative of n 4 independent
experiments.






/nar/article-abstract/41/20/9471/2414802 by guest on 15 June 2020
total protein synthesis. Rather, at 45 uM, 8-Aza induced
significant alterations in viral RNA splicing as well as a
block in viral RNA export because of a shift in Rev
subcellular distribution.
In the case of splicing, treatment with 8-Aza resulted in
a significant reduction in accumulation of the incom-
pletely spliced (US and SS) viral RNAs with a slight
increase in MS viral RNA levels, consistent with induction
of oversplicing or a reduced stability of the incompletely
spliced viral RNAs. In addition, we detected a shift in the
pattern of splice site usage within the viral MS RNAs with
a dramatic increase in the generation of Nef1 RNA, cor-
responding to the joining of the first 50ss of HIV-1 (SD1)
to the last 30ss (SA7), and a reduction in Nef2 RNA levels.
Analysis of the effect of 8-Aza on host RNA splicing
revealed some perturbations, but only to a limited
number of the splicing events analysed and none to the
same extent as observed for HIV-1. In light of the known
incorporation of 8-Aza into RNA, it may be acting to
alter recognition of splicing regulatory sequences by host
Figure 7. 8-Aza and 5350150 inhibit HIV-1 replication by altering viral RNA processing. This diagram outlines the stages of RNA processing during
the HIV-1 life cycle. This study demonstrates that 8-Aza and 5350150 are potent inhibitors of HIV-1 replication that perturb viral RNA processing, a
stage of the virus life cycle not targeted by current anti-retroviral therapies. 8-Aza and 5350150 inhibit the virus by altering specific pre-mRNA
splicing events under the control/influence of the host. This includes (i) inducing oversplicing of HIV-1 pre-mRNA (depicted by an increasingly
yellow arrow), which reduces both US and SS mRNA levels (with the exception of 5350150 on SS mRNA), and (ii) altering the localization of HIV-1
Rev, resulting in sequestration of incompletely spliced (US and SS) RNAs to the cell nucleus. Both of these mechanisms lead to a reduction in US
and SS viral mRNAs available for translation, perturbing the synthesis of a subset of HIV-1 regulatory and accessory factors as well as structural
proteins/enzymes necessary for new virion assembly and infection. This study confirms that small molecule inhibitors that alter viral RNA processing
can potently inhibit HIV-1 replication, signifying the potential of directing novel therapeutics to this stage for control of this disease.
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factors. Consistent with this possibility, mutational inacti-
vation of the purine-rich GAR exon splicing enhancer
adjacent to the major 50ss of Env (SD4) results in
increased accumulation of Nef1 similar to the effect seen
with 8-Aza treatment (46). Alternatively, incorporation
into hnRNP A1 binding sites (consensus UAGGG)
throughout the viral RNA may interfere with the ability
of hnRNP A1 to suppress HIV-1 splice site usage (15,47),
potentially explaining the oversplicing phenotype
observed. Although the incorporation of 8-Aza into
RNA could explain some of the effects on viral RNA
processing, the mechanism underlying its effect on Rev
function is less apparent. The rapid shift in the subcellular
distribution of Rev on 8-Aza addition, coupled with the
block in accumulation of HIV-1 US RNA in the cyto-
plasm, is consistent with an inhibition of Rev function.
The ability of LB treatment to reverse the effect of 8-
Aza on Rev localization indicates that this compound
does not prevent Rev shuttling but rather alters the
relative rates of Rev nuclear import and export, from
favouring nuclear import to preferring nuclear export.
However, the inability of 8-Aza to alter the subcellular
distribution of other known shuttling proteins (hnRNP
A1 and SRp20) indicates that its mechanism is likely se-
lective for factors regulating Rev movement. Taken
together, the data (summarized in Figure 7) suggest that
8-Aza functions to suppress HIV-1 structural gene expres-
sion by (1) inducing oversplicing or altering stability of the
viral RNA to reduce the amount of US and SS RNA
available for export/translation and (2) reduce the level
of Rev in the nucleus, impairing the transport of the US
and SS RNAs to the cytoplasm. The determination that 8-
Aza is also able to suppress HIV-1 expression in the
context of a T cell line and PBMCs indicates that it is
affecting a common pathway across multiple cell lines.
The suppression of HIV-1 gene expression by 5350150
appears to occur through a distinct mechanism than
8-Aza. The 5350150 addition resulted in more limited al-
terations in abundance of the various HIV-1 RNAs and
no significant shift in splice site usage. Assays measuring
the effects of 5350150 on host alternative RNA splicing
did not detect any marked changes, indicating that the
compound is acting in a highly selective manner.
Subsequent analyses indicate that 5350150 suppresses
HIV-1 structural protein (Gag and Env) expression by
affecting Rev function, as evidenced by the shift in Rev
subcellular distribution and the absence of HIV-1 US
RNA in the cytoplasm on treatment (Figure 7).
Furthermore, 5350150 induces these alterations in a
fashion distinct from either 8-Aza or Act. D as suggested
by the slower kinetics of Rev relocalization to the cyto-
plasm and the failure of LB to fully induce nuclear accu-
mulation of Rev. The latter observation suggests that
5350150 may be acting to impair components of Rev
nuclear import. However, the slow kinetics of the change
in Rev localization on addition of 5350150 raises the pos-
sibility that the effect seen is indirect, mediated by altering
the abundance of factors regulating Rev movement. As
with 8-Aza, the absence of any alteration in distribution
of other shuttling proteins (hnRNP A1 or SRp20) suggests
that the net effect of 5350150 is likely selective to Rev.
Analysis of structural variants of 5350150 that retain or
lose activity will be of critical importance in further
defining its mechanism of action.
Although the documented toxicity of 8-Aza may
preclude its direct use for the suppression of HIV-1 repli-
cation in humans, the capacity of both small molecule
inhibitors to suppress expression from integrated HIV-1
provirus in multiple systems serves as proof that this stage
of the virus life cycle can be effectively targeted by such
agents. The distinct effects of 8-Aza and 5350150, but a
similar result on viral protein expression (loss of HIV-1
Gag and Env), highlight the fact that there are multiple
ways of achieving a post-transcriptional block to HIV-1
gene expression. In addition, as our understanding of their
mode of action increases (in particular, the host factors
being affected), we will be able to refine our approach to
enhance the activity towards the protein targets of interest
while minimizing off target effects. Targeting this stage of
the HIV-1 life cycle has the potential to greatly synergize
with existing therapeutics, providing a more robust barrier
to the evolution of resistance, or serve as a second-line
treatment regimen in cases when first-line therapies are
unsuccessful.
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